参考文献/References:
[1].1] Mehran R,Dangas G,Abizaid AS,et al. Angiographic patterns of in-stent restenosis:classification and implications for long-term outcome[J]. Circulation,1999,100(18):1872-1878.
[2].[2] Nakazawa G,Otsuka F,Nakano M,et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents[J]. J Am Coll Cardiol,2011,57(11):1314-1322.
[3].[3] Xhepa E,Byrne RA,Rivero F,et al. Qualitative and quantitative neointimal characterization by optical coherence tomography in patients presenting with in-stent restenosis[J]. Clin Res Cardiol,2019,108(9):1059-1068.
[4].[4] Jenei C,Balogh E,Szabó GT,et al. Wall shear stress in the development of in-stent restenosis revisited. A critical review of clinical data on shear stress after intracoronary stent implantation[J]. Cardiol J,2016,23(4):365-373.
[5].[5] Bangalore S,Bhatt DL. Coronary intravascular ultrasound[J]. Circulation,2013,127(25):e868-e874.
[6].[6] Steinvil A,Zhang YJ,Lee SY,et al. Intravascular ultrasound-guided drug-eluting stent implantation:an updated meta-analysis of randomized control trials and observational studies[J]. Int J Cardiol,2016,216:133-139.
[7].[7] Ha FJ,Giblett JP,Nerlekar N,et al. Optical coherence tomography guided percutaneous coronary intervention[J]. Heart Lung Circ,2017,26(12):1267-1276.
[8].[8] Kuku KO,Ekanem E,Azizi V,et al. Optical coherence tomography-guided percutaneous coronary intervention compared with other imaging guidance:a meta-analysis[J]. Int J Cardiovasc Imaging,2018,34(4):503-513.
[9].[9] Gerbaud E,Weisz G,Tanaka A,et al. Multi-laboratory inter-institute reproducibility study of IVOCT and IVUS assessments using published consensus document definitions[J]. Eur Heart J Cardiovasc Imaging,2016,17(7):756-764.
[10].[10] Kume T,Uemura S. Current clinical applications of coronary optical coherence tomography[J]. Cardiovasc Interv Ther,2018,33(1):1-10.
[11].[11] Levine GN,Bates ER,Blankenship JC,et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions[J]. J Am Coll Cardiol,2011,58(24):e44-e122
[12].[12] Sousa-Uva M,Neumann FJ,Ahlsson A,et al. 2018 ESC/EACTS guidelines on myocardial revascularization[J]. Eur J Cardiothorac Surg,2019,55(1):4-90.
[13].[13] R?ber L,Mintz GS,Koskinas KC,et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions[J]. EuroIntervention,2018,14(6):656-677.
[14].[14] Fujii K,Carlier SG,Mintz GS,et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation:an intravascular ultrasound study[J]. J Am Coll Cardiol,2005,45(7):995-998.
[15].[15] Fujita T,Takeda T,Hano Y,et al. Post-intervention minimal stent area as a predictor of target lesion revascularization after everolimus-eluting stent implantation for in-stent restenosis:a single-center observational study[J]. Coron Artery Dis,2019,30(6):432-439.
[16].[16] Choi SY,Witzenbichler B,Maehara A,et al. Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction:a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy[J]. Circ Cardiovasc Interv,2011,4(3):239-247.
[17].[17] Song HG,Kang SJ,Ahn JM,et al. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-,everolimus-,and sirolimus-eluting stent implantation[J]. Catheter Cardiovasc Interv,2014,83(6):873-878.
[18].[18] Matsuo Y,Kubo T,Aoki H,et al. Optimal threshold of postintervention minimum stent area to predict in-stent restenosis in small coronary arteries:an optical coherence tomography analysis[J]. Catheter Cardiovasc Interv,2016,87(1):E9-E14.
[19].[19] Miura K,Tada T,Habara S,et al. Optical coherence tomography predictors for recurrent restenosis after paclitaxel-coated balloon angioplasty for drug-eluting stent restenosis[J]. Circ J,2018,82(11):2820-2828.
[20].[20] Ino Y,Kubo T,Matsuo Y,et al. Optical coherence tomography predictors for edge restenosis after everolimus-eluting stent implantation[J]. Circ Cardiovasc Interv,2016,9(10):e004231.
[21].[21] Soeda T,Uemura S,Park SJ,et al. Incidence and clinical significance of poststent optical coherence tomography findings:one-year follow-up study from a multicenter registry[J]. Circulation,2015,132(11):1020-1029.
[22].[22] Bryniarski KL,Tahk SJ,Choi SY,et al. Clinical,angiographic,IVUS,and OCT predictors for irregular protrusion after coronary stenting[J]. EuroIntervention,2017,12(18):e2204-e2211.
[23].[23] Mintz GS. Clinical utility of intravascular imaging and physiology in coronary artery disease[J]. J Am Coll Cardiol,2014,64(2):207-222.
[24].[24] Inaba S,Mintz GS,Yun KH,et al. Mechanical complications of everolimus-eluting stents associated with adverse events:an intravascular ultrasound study[J]. EuroIntervention,2014,9(11):1301-1308.
[25].[25] Ali ZA,Roleder T,Narula J,et al. Increased thin-cap neoatheroma and periprocedural myocardial infarction in drug-eluting stent restenosis:multimodality intravascular imaging of drug-eluting and bare-metal stents[J]. Circ Cardiovasc Interv,2013,6(5):507-517.
[26].[26] Park SJ,Kang SJ,Virmani R,et al. In-stent neoatherosclerosis:a final common pathway of late stent failure[J]. J Am Coll Cardiol,2012,59(23):2051-2057.
[27].[27] Araki T,Nakamura M,Sugi K. Characterization of in-stent neointimal tissue components following drug-eluting stent implantation according to the phase of restenosis using a 40-MHz intravascular ultrasound imaging system[J]. J Cardiol,2014,64(6):423-429.
[28].[28] Song L,Mintz GS,Yin D,et al. Characteristics of early versus late in-stent restenosis in second-generation drug-eluting stents:an optical coherence tomography study[J]. EuroIntervention,2017,13(3):294-302.
[29].[29] Feng C,Zhang P,Han B,et al. Optical coherence tomographic analysis of drug-eluting in-stent restenosis at different times:a STROBE compliant study[J]. Medicine(Baltimore),2018,97(34):e12117.
[30].[30] Otsuka F,Byrne RA,Yahagi K,et al. Neoatherosclerosis:overview of histopathologic findings and implications for intravascular imaging assessment[J]. Eur Heart J, 2015,36(32):2147-2159.
[31].[31] Araki M,Yonetsu T,Lee T,et al. Relationship between optical coherence tomography-defined in-stent neoatherosclerosis and out-stent arterial remodeling assessed by serial intravascular ultrasound examinations in late and very late drug-eluting stent failure[J]. J Cardiol,2018,71(3):244-250.
[32].[32] Jensen LO,Vikman S,Antonsen L,et al. Intravascular ultrasound assessment of minimum lumen area and intimal hyperplasia in in-stent restenosis after drug-eluting or bare-metal stent implantation. The Nordic Intravascular Ultrasound Study(NIVUS)[J]. Cardiovasc Revasc Med,2017,18(8):577-582.
[33].[33] Goto K,Takebayashi H,Kihara Y,et al. Appearance of neointima according to stent type and restenotic phase:analysis by optical coherence tomography[J]. EuroIntervention,2013,9(5):601-607.
[34].[34] Nakamura D,Yasumura K,Nakamura H,et al. Different neoatherosclerosis patterns in drug-eluting- and bare-metal stent restenosis—Optical Coherence Tomography Study[J]. Circ J,2019,83(2):313-319.
[35].[35] Song L,Mintz GS,Yin D,et al. Neoatherosclerosis assessed with optical coherence tomography in restenotic bare metal and first- and second-generation drug-eluting stents[J]. Int J Cardiovasc Imaging,2017,33(8):1115-1124.
[36].[36] Kajiya T,Yamaguchi H,Takaoka J,et al. In-stent restenosis assessed with frequency domain optical coherence tomography shows smooth coronary arterial healing process in second-generation drug-eluting stents[J]. Singapore Med J,2019,60(1):48-51
[37].[37] Chavarria J,Suarez de Lezo J,Ojeda S,et al. Restenosis after everolimus-eluting vascular scaffolding. Angiographic and optical coherence tomography characterization[J]. Rev Esp Cardiol(Engl Ed),2017,70(7):543-550
[38].[38] Wolny R,Mintz GS,Matsumura M,et al. Intravascular ultrasound assessment of in-stent restenosis in saphenous vein grafts[J]. Am J Cardiol,2019,123(7):1052-1059.
[39].[39] Gao L,Park SJ,Jang Y,et al. Comparison of neoatherosclerosis and neovascularization between patients with and without diabetes:an optical coherence tomography study[J]. JACC Cardiovasc Interv,2015,8(8):1044-1052.
[40].[40] de la Torre Hernandez JM,Garcia Camarero T,Lozano Ruiz-Poveda F,et al. Angiography and optical coherence tomography assessment of the drug-coated balloon essential for the treatment of in-stent restenosis[J]. Cardiovasc Revasc Med,2020,21(4):508-513.
[41].[41] Yin D,Mintz GS,Song L,et al. In-stent restenosis characteristics and repeat stenting underexpansion:insights from optical coherence tomography[J]. EuroIntervention,2020,16(4):e335-e343.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(3):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(3):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(3):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(3):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(3):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(3):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(3):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(3):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(3):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]